TNF and myeloid sarcoma: Furthermore, as IL-6 secretion decreases, IL-10 as an anti-inflammatory marker and TNF-α as a proinflammatory marker increase and decrease, respectively [38,43], which can manage and improve MS pathogenic functions such as axonal transection and demyelination [17].